Abstract:Objective: To assess the average bioequivalence of two formulations of metformin after single-dose administration of each treatment to healthy subjects under fasting conditions by assessing the pharmacokinetic measures of systemic exposure and evaluating the confidence intervals (CIs) for each pharmacokinetic parameter.Design: Randomised, comparative, single-dose, open-label, balanced, two-period, two-treatment, crossover study under fasting conditions. Participants: 20 healthy volunteers (ten men and ten women) took part in the study.Methods: Subjects were investigated after a single dose of 850mg after a washout period of 7 days. Plasma samples were taken at regular time intervals according to the study protocol for measuring plasma metformin concentrations. Systemic exposure was estimated with the use of pharmacokinetic parameters (area under the curve of the plasma drug concentrations from time zero to the last sampling time [AUC0-36], area under the curve of the plasma drug concentrations from time zero to infinity [AUC0-∞], time to peak drug concentration [tmax], partial area under the concentration-time curve with a cut-off point at the tmax of the reference product [AUCp], peak plasma drug concentration [Cmax], the ratio Cmax/AUC0-∞, and mean residence time [MRT]). The point estimates of pharmacokinetic parameters (geometric means of the ratios test [T]/reference [R] and the 90% CIs for the ratios of geometric means [T]/[R]), estimated by parametric and nonparametric analysis, were used in the statistical analysis.Results: The point estimates and the 90% CIs after parametric analysis of AUC0-∞ were 0.98 and (0.96–1.21), and after nonparametric analysis were 1.06 and (0.95–1.207), respectively. The two drug products were considered to be bioequivalent and with significant variability across subjects for the pharmacokinetic parameters AUC0–36, AUC0-∞, Cmax and MRT according to analysis of variance of log-transformed data.Conclusions: The two studied formulations of metformin were found to be bioequivalent. They showed similar extents and rates of absorption and similar exposure. However, analysis of variance of logarithmically transformed data revealed significant variability among individuals in AUC0–36, AUC0-∞ and Cmax, making careful individualisation of the metformin dosage important.

Study of bioequivalence of compound metformin hydrochloride tablet in healthy volunteers

Pharmacokinetics and bioequivalance of domestic compound glibenclamide and metformin in chinese healthy volunteers

Relative bioavailability of compound metformin hydrochloride tablets in healthy volunteers

Pharmacokinetics of glibenclamide/metformin hydrochloride combination

Bioequivalence of Two Domestic Praperations of Metformin Hydrochloride Entericcoated Capsules in Chinese Healthy Volunteers

Pharmacokinetics and relative bioavailability of compound metformin hydrochloride tablet in healthy volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Pharmacokinetics and Bioequivalence of Compound Mefformin Hydrochloride Tablets in Healthy Volunteers

Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Study of the Bioequivalence of Gliclazide in Chinese Healthy Volunteers

Bioequivalence of gliclazide tablets in Chinese healthy volunteers

Pharmacokinetics and Relative Bioavailability of Metformin Extended-release Tablets in Healthy Volunteers

Study on the relative bioavailability of metformin hydrochloride sustained-release tablets

Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers

Pharmacokinetics and Comparative Bioavailability of Two Metformin Formulations after Single-Dose Administration in Healthy Subjects

Bioequivalence of glipizide orally disintegrating tablets in healthy volunteers

Bioequivalence of Gliclazide Sustained Release Tablets

Relative Bioavailability and Bioequivalence of Metforphin Hydrochloride Extended-Released and Immediate-Released Tablets in Healthy Chinese Volunteers

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

Bioequivalence of Repaglinide in Healthy Volunteers

Post-Marketing Reevaluation on Bioequivalence of Metformin Hydrochloride Tablets